Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

lifesciences-antc-boston-forum-merger-control-and-competition

Join Goodwin for a lively discussion on antitrust in life sciences transactions, featuring expert insights and a panel of industry leaders.

Boston Forum: Merger Control & Competition in Life Sciences

Summary

Speakers

Arman Oruc

Andrew Lacy

Sarah Jordan

Stephen C. Mavroghenis

Related Content

Delaware's Corporate Advantages May Outweigh Benefits of Relocation

US Emerging as Top Global Medtech Destination

Federal Circuit Affirms Injunction Against Celltrion in Aflibercept BPCIA Litigation

Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 and Anti-CTLA-4 Antibody Combination Method of Treatment Patents

FDA Approves Celltrion’s Denosumab Biosimilars

Where were biologics-related patents involved in BPCIA litigation invented?

European Commission Approves Celltrion’s AVTOZMA (CT-P47)

Goodwin’s 2025 Rare Disease Symposium: Momentum Builds for Addressing Critical Diagnosis and Treatment Gaps

Goodwin’s Annual Healthcare & Life Sciences Summit

2seventy bio To Be Acquired by Bristol Myers Squibb for $5.00 per Share

BridgeBio Pharma Prices $575 Million Convertible Notes Offering

Yale OCS STEM PhD Pathways: Navigating Career Paths in Patent Law with Miho Kaneko

Teleflex to Acquire BIOTRONIK’s Vascular Intervention Business For €760 Million

Bpifrance and Andera Partners Invest in the €27 Million Series B Financing of EG 427

Goodwin Advises Atrandi Biosciences in $25M Series A Financing

Stilla Technologies and the Sellers Sign a Put Option Agreement for the Acquisition of Stilla Technologies by Bio-Rad

Life Sciences

Antitrust & Competition